Under the UK’s 2021 G7 Presidency, Finance Ministers committed to take additional steps to address antibiotic market failure and create economic conditions to preserve essential existing antibiotics and ensure their access, strengthen antimicrobial resistance (AMR) research and development (R&D), and bring new drugs to market. To support this work, G7 Finance Ministers requested the Global AMR R&D Hub and WHO prepare a progress update for G7 Finance and Health Ministers in 2022. The 2022 Progress Report for G7 Ministers jointly written by the Global AMR R&D Hub and WHO provides an update on the current antibacterial treatment and vaccine pipelines, the financial landscape for developing new antimicrobials, and recommendations for future action.
Key recommendations from the 2022 Progress Report:
- Maintain push funding for AMR R&D: establish global R&D targets based on patient needs and encourage specific national commitments; strengthen R&D targeting priority bacterial pathogens and missing vaccines that address urgent public health needs; build on investment in early stage product development and further support later stage clinical development; provide coverage across the R&D pipeline.
- Increase and coordinate pull incentives: implement a coordinated and aligned global pull incentive focusing on urgent public health needs; prioritise and accelerate efforts to develop and implement new innovative delinked pull incentive models.
- Advance equity and access through AMR development cooperation: take up access to priority antibiotics as a key factor in mitigating the AMR response; encourage development cooperation agencies to expand their remits to include AMR.
